Paper Chase is a research database designed to offer abstracts of research articles published in journals that have a highly rated impact factor as determined by ISI Impact Factor and PageRank. Abstracts are organized by date, with the most recently published papers listed first. 

Paper Chase

61.

Ventricular arrhythmias and sudden cardiac death.

Lancet.
John RM, Tedrow UB, Koplan BA, Albert CM, Epstein LM, Sweeney MO, Miller AL, Michaud GF, Stevenson WG.
| Oct 27, 2012
62.

Postoperative radiation for prostate cancer.

Lancet.
Efstathiou JA.
| Dec 8, 2012
63.

Health-care reforms in the USA and England: areas for useful learning.

Lancet.
Blumenthal D, Dixon J.
| Oct 13, 2012
64.

EXAMINATION of new drug-eluting stents--top of the class!

Lancet.
Bhatt DL.
| Oct 27, 2012
65.

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Lancet.
Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ, Zucchiatti N.
| Oct 20, 2012
66.

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.

Lancet.
Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow DA.
| Oct 13, 2012
67.

How much CABG is good for us?

Lancet.
Jones DS.
| Aug 11, 2012
68.

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.

Lancet.
Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ.
| Aug 11, 2012
70.

Comprehensive clinical care for men who have sex with men: an integrated approach.

Lancet.
Mayer KH, Bekker LG, Stall R, Grulich AE, Colfax G, Lama JR.
| Jul 28, 2012
71.

Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy.

Lancet.
Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, Alkandari JR.
| Jul 21, 2012
72.

Cholera.

Lancet.
Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB.
| Jun 30, 2012
73.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

Lancet.
Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK, Akil B.
| Jun 30, 2012
74.

Pulmonary embolism and deep vein thrombosis.

Lancet.
Goldhaber SZ, Bounameaux H.
| May 12, 2012
75.

Are we ready to recommend aspirin for cancer prevention?

Lancet.
Chan AT, Cook NR.
| Apr 28, 2012
76.

Towards regenerative therapy for cardiac disease.

Lancet.
Ptaszek LM, Mansour M, Ruskin JN, Chien KR.
| Mar 10, 2012
77.

Improving medication safety.

Lancet.
Schnipper JL, Rothschild JM.
| Apr 7, 2012
78.

Survival of children with burn injuries.

Lancet.
Tompkins RG.
| Mar 17, 2012
79.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Lancet.
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M, Lerzo G.
| Feb 18, 2012